Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Azeem MI, Nooka AK, Shanmugasundaram U, Cheedarla N, Potdar S, Manalo RJ, Moreno A, Switchenko JM, Cheedarla S, Doxie DB, Radzievski R, Ellis ML, Manning KE, Wali B, Valanparambil RM, Maples KT, Baymon E, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Roback JD, Sette A, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV, Dhodapkar KM. Azeem MI, et al. Among authors: manning ke. Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173. Blood Cancer Discov. 2023. PMID: 36511813 Free PMC article.
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
Moreno A, Manning K, Azeem MI, Nooka AK, Ellis M, Manalo RJ, Switchenko JM, Wali B, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV, Suthar MS. Moreno A, et al. Among authors: manning k. Res Sq [Preprint]. 2023 Sep 21:rs.3.rs-3293339. doi: 10.21203/rs.3.rs-3293339/v1. Res Sq. 2023. Update in: NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6 PMID: 37790523 Free PMC article. Updated. Preprint.
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, Chang A, McCook-Veal AA, Switchenko J, Nasti TH, Saini M, Wieland A, Manning KE, Ellis M, Moore KM, Foster SL, Floyd K, Davis-Gardner ME, Edara VV, Patel M, Steur C, Nooka AK, Green F, Johns MA, O'Brein F, Shanmugasundaram U, Zarnitsyna VI, Ahmed H, Nyhoff LE, Mantus G, Garett M, Edupuganti S, Behra M, Antia R, Wrammert J, Suthar MS, Dhodapkar MV, Ramalingam S, Ahmed R. Valanparambil RM, et al. Among authors: manning ke. J Clin Oncol. 2022 Nov 20;40(33):3808-3816. doi: 10.1200/JCO.21.02986. Epub 2022 Jun 27. J Clin Oncol. 2022. PMID: 35759727 Free PMC article.
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Lyke KE, et al. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. NPJ Vaccines. 2023. PMID: 37433788 Free PMC article.
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
Moreno A, Manning K, Azeem MI, Nooka AK, Ellis M, Manalo RJ, Switchenko JM, Wali B, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV, Suthar MS. Moreno A, et al. Among authors: manning k. bioRxiv [Preprint]. 2023 Aug 22:2023.08.17.553767. doi: 10.1101/2023.08.17.553767. bioRxiv. 2023. Update in: NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6 PMID: 37662390 Free PMC article. Updated. Preprint.
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.
Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore K, Floyd K, Foster SL, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Roberts PC, Beigel J, Korber B, Pajon R, Mascola JR, Suthar MS, Montefiori DC. Doria-Rose NA, et al. Among authors: manning ke. medRxiv [Preprint]. 2021 Dec 20:2021.12.15.21267805. doi: 10.1101/2021.12.15.21267805. medRxiv. 2021. Update in: N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912 PMID: 34931200 Free PMC article. Updated. Preprint.
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
Edara VV, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-Gardner ME, Mantus G, Nyhoff LE, Bechnak S, Alaaeddine G, Naji A, Samaha H, Lee M, Bristow L, Gagne M, Roberts-Torres J, Henry AR, Godbole S, Grakoui A, Saxton M, Piantadosi A, Waggoner JJ, Douek DC, Rouphael N, Wrammert J, Suthar MS. Edara VV, et al. Among authors: manning ke. Cell Rep Med. 2022 Jan 24;3(2):100529. doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233550 Free PMC article.
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination.
Mantus G, Nyhoff LE, Edara VV, Zarnitsyna VI, Ciric CR, Flowers MW, Norwood C, Ellis M, Hussaini L, Manning KE, Stephens K, Anderson EJ, Ahmed R, Suthar MS, Wrammert J. Mantus G, et al. Among authors: manning ke. Cell Rep Med. 2022 Mar 29;3(4):100603. doi: 10.1016/j.xcrm.2022.100603. eCollection 2022 Apr 19. Cell Rep Med. 2022. PMID: 35480625 Free PMC article.
563 results